MTVA
NeuroBo Pharmaceuticals Inc (MTVA)
Healthcare • NASDAQ • $1.09-18.05%
- Symbol
- MTVA
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $1.09
- Daily Change
- -18.05%
- Market Cap
- $5.63M
- Trailing P/E
- N/A
- Forward P/E
- N/A
- 52W High
- $19.03
- 52W Low
- $1.00
- Analyst Target
- $19.33
- Dividend Yield
- N/A
- Beta
- 0.58
MetaVia Inc., a clinical-stage biotechnology company, focuses on developing novel pharmaceuticals to treat cardiometabolic diseases. The company develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, as well as completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in Phase 1 trial for the treatment of obesity. Its therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the t…
Company websiteResearch MTVA on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.